All IndicationsOncologyApprovedApprovedPhase 3Phase 3Phase 3Phase 2Phase 2
🎗️
Pancreatic Cancer
11
Companies
11
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
TRAX
Trax Pharmaceuticals
daraxonrasib
RVMD
Revolution Medicines
Rasonque
ALPMY
Astellas Pharma
Setidegrasib
APTOF
Aptose Biosciences Inc.
Virulizin®
RVMDW
Revolution Medicines, Inc.
daraxonrasib
XBIT
XBiotech Inc.
XB2001 or Placebo
GRTX
Galera Therapeutics, Inc.
GC4419
TNGX
Tango Therapeutics
Tango pancreatic cancer combination
FVNNU
Forty Seven Inc
RASolute 302
ADPT
Adaptative
SBRT
PPCB
Propanc Biopharma
PRP
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| TRAX Trax Pharmaceuticals | daraxonrasib | Approved | — | — | — |
| RVMD Revolution Medicines | Rasonque | Approved | — | — | — |
| ALPMY Astellas Pharma | Setidegrasib | Phase 3 | — | — | — |
| APTOF Aptose Biosciences Inc. | Virulizin® | Phase 3 | — | — | — |
| RVMDW Revolution Medicines, Inc. | daraxonrasib | Phase 3 | — | — | — |
| XBIT XBiotech Inc. | XB2001 or Placebo | Phase 2 | — | — | — |
| GRTX Galera Therapeutics, Inc. | GC4419 | Phase 2 | — | — | — |
| TNGX Tango Therapeutics | Tango pancreatic cancer combination | — | — | — | — |
| FVNNU Forty Seven Inc | RASolute 302 | — | — | — | — |
| ADPT Adaptative | SBRT | — | — | — | — |
| PPCB Propanc Biopharma | PRP | — | — | — | — |
Development Stage Distribution
Unknown
4
Approved
2
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.